OncoBay Clinical Aims to Accelerate Immuno-Oncology Research
New immunotherapy-focused contract research organization offers end-to-end services for pharmaceutical and biotech companies
TAMPA, Fla. (June 05, 2020) — Oncology research is transformed from the therapies tested and delivered less than a decade ago to those delivered today. In 2019, more than 400 immunotherapy products were available to patients and over 400 more were in development. These innovative therapies change the way we treat and manage patients. At OncoBay Clinical we know that new treatments with added complexities and unique safety profiles require a new approach, not just a band-aid on old methods. Innovation requires innovation. Introducing OncoBay Clinical, the next generation of CRO support.
OncoBay Clinical, is a first-of-its-kind immuno-oncology contract research organization (CRO) specializing in rare and complex Oncology indications including Immunotherapies and cellular therapies. A boutique CRO, OncoBay is a wholly owned for-profit subsidiary of Moffit Cancer Center. As an NCI-designated Comprehensive Cancer Center, Moffit has been at the forefront of development and research. Through direct partnership, OncoBay Clinical now leverages the unrivaled support of Moffit’s top scientific advisors imbedding scientific expertise into every project team and creating “vein to vein” control of Cell Therapy (CTx) trials including those focused on tumor infiltrating lymphocyte (TIL) and chimeric antigen receptor T-cell (CAR T) therapies.
“OncoBay is filling a much-needed space in the industry, innovating in a way that is unprecedented. Our model revolutionizes the approach to oncology clinical trials and has been designed and built based upon the most difficult trials as a framework, thus allowing us to succeed in managing the most complex programs.” said Krystyna Kowalczyk, president and CEO of OncoBay Clinical. “Through our partnership with Moffitt Cancer Center, OncoBay Clinical has the ability to integrate scientific expertise with operational excellence and manufacturing capabilities to provide full service, custom curated solutions for our clients.”
OncoBay Clinical is a full-service boutique CRO offering end-to-end services for pharmaceutical and biotech companies. Specializing in immuno-oncology clinical trials, OncoBay boasts a respected team of executive leaders with over 100 years of oncology operations experience, all of whom are personally dedicated to the success of IO clinical trials from start to finish.
To learn more about OncoBay Clinical, please visit www.OncoBay.com.
About OncoBay Clinical
OncoBay Clinical is a boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full- service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As a wholly owned, for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit Oncobay.com and follow us on Facebook, Twitter and LinkedIn.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
Director Sales, Business Development